BMS Signs a Research Collaboration with Presage to Evaluate Novel Cancer Therapies In Phase 0 Studies Utilizing CIVO Technology

 BMS Signs a Research Collaboration with Presage to Evaluate Novel Cancer Therapies In Phase 0 Studies Utilizing CIVO Technology

BMS Signs a Research Collaboration with Presage to Evaluate Novel Cancer Therapies In Phase 0 Studies Utilizing CIVO Technology

Shots:

  • Presage and BMS enter into a research collaboration to assess early stage oncology targets in P-0 studies by evaluating patients’ unique responses to micro doses of multiple cancer therapies
  • The focus of the collaboration is to expand the use of Presage’s CIVO technology in P-0 studies and is the third partnership of Presage for utilizing its CIVO platform to investigate tumor cell and microenvironment responses of therapies in P-0 studies
  • CIVO is a micro dosing platform that enables simultaneous assessment of responses for multiple cancer therapies or combinations therapies directly in a single tumor while still in a patient’s body

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Financial News

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post